Improving growth and development in children with growth hormone deficiency through transdermal treatment of acupoints with the tonifying spleen and kidney method in conjunction with growth hormone therapy.

Researchers in China examined whether combining acupuncture-based treatment with standard growth hormone therapy could help children with growth hormone deficiency grow better. The study looked at 115 children, comparing those who received only growth hormone injections (62 children) with those who received both growth hormone and a special acupuncture treatment called transdermal acupoint therapy (53 children). The acupuncture approach used Traditional Chinese Medicine principles focused on strengthening the spleen and kidney systems. After one year of treatment, children who received the combined approach showed significant improvements compared to those receiving only growth hormone therapy. The combined treatment group had better bone mineral density at multiple body sites, meaning stronger bones. They also showed improved physical growth measurements overall. Additionally, the combined approach helped balance several important hormones in the body, including insulin-like growth factor-1, thyroid hormones, and sex hormones. The acupuncture treatment did not cause any additional side effects compared to growth hormone therapy alone. This suggests that adding transdermal acupoint therapy to standard growth hormone treatment may be a safe and effective way to enhance growth and development in children with growth hormone deficiency. The treatment appeared to work by supporting both the endocrine (hormone) system and physical development. If you're considering acupuncture for your child's growth concerns, consult with a licensed acupuncturist experienced in pediatric care and Traditional Chinese Medicine.

This retrospective analysis evaluated transdermal acupoint therapy using the tonifying spleen and kidney method combined with growth hormone (GH) treatment in 115 pediatric patients with growth hormone deficiency (GHD). The combined therapy group (n=53) was compared with conventional GH treatment alone (n=62) over one year. Results demonstrated statistically significant improvements in the combined group across multiple parameters: lower levels of IGF-1, testosterone, estrogen, TSH, IGFBP-3, and free thyroxine (all P<0.001 except IGFBP-3 P=0.009); significantly higher bone mineral density at multiple sites (P<0.05); and improved physical growth parameters (P<0.05). No increase in adverse events was observed with combined therapy. The transdermal acupoint treatment showed significant correlations with various growth and development indexes. Clinical takeaway: Integrating transdermal acupoint therapy with tonifying spleen and kidney principles alongside standard GH therapy appears to enhance endocrine regulation, bone development, and physical growth outcomes in pediatric GHD patients without additional safety concerns.